13 research outputs found
Ebola: translational science considerations
We are currently in the midst of the most aggressive and fulminating outbreak of Ebola-related disease, commonly referred to as “Ebola”, ever recorded. In less than a year, the Ebola virus (EBOV, Zaire ebolavirus species) has infected over 10,000 people, indiscriminately of gender or age, with a fatality rate of about 50%. Whereas at its onset this Ebola outbreak was limited to three countries in West Africa (Guinea, where it was first reported in late March 2014, Liberia, where it has been most rampant in its capital city, Monrovia and other metropolitan cities, and Sierra Leone), cases were later reported in Nigeria, Mali and Senegal, as well as in Western Europe (i.e., Madrid, Spain) and the US (i.e., Dallas, Texas; New York City) by late October 2014. World and US health agencies declared that the current Ebola virus disease (EVD) outbreak has a strong likelihood of growing exponentially across the world before an effective vaccine, treatment or cure can be developed, tested, validated and distributed widely. In the meantime, the spread of the disease may rapidly evolve from an epidemics to a full-blown pandemic. The scientific and healthcare communities actively research and define an emerging kaleidoscope of knowledge about critical translational research parameters, including the virology of EBOV, the molecular biomarkers of the pathological manifestations of EVD, putative central nervous system involvement in EVD, and the cellular immune surveillance to EBOV, patient-centered anthropological and societal parameters of EVD, as well as translational effectiveness about novel putative patient-targeted vaccine and pharmaceutical interventions, which hold strong promise, if not hope, to curb this and future Ebola outbreaks. This work reviews and discusses the principal known facts about EBOV and EVD, and certain among the most interesting ongoing or future avenues of research in the field, including vaccination programs for the wild animal vectors of the virus and the disease from global translational science perspective
Production and Characterization of Antimicrobial Electrospun Nanofibers Containing Polyurethane, Zirconium Oxide and Zeolite
Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors
Antibacterial effects of silver–zirconia composite coatings using pulsed laser deposition onto 316L SS for bio implants
Crystal structure and improved dielectric, magnetic, ferroelectric and magneto-electric properties of xCoFe2O4−(1−x)BaTiO3 multiferroic composites
Synthesis and structural properties characterization of titania/zirconia/calcium silicate nanocomposites for biomedical applications
Evaluation Physical Characteristics and Comparison Antimicrobial and Anti-Inflammation Potentials of Dental Root Canal Sealers Containing Hinokitiol In Vitro
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA
Hepatitis C virus (HCV) is an unusual RNA virus that possesses a striking capacity to persist for life in the majority of infected individuals. In order to persist, HCV must balance viral RNA synthesis and decay in infected cells. In this Review, we focus on interactions between the positive-sense RNA genome of HCV and host RNA-binding proteins and microRNAs (miRNAs) that influence the competing processes of viral RNA synthesis and decay to achieve stable, long-term persistence of the viral genome. We discuss how these processes impact HCV pathogenesis and therapeutic strategies against the virus